NCT01374087 - Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Prostate Cancer

Interventions

DRUG

Triptorelin 22.5 mg

Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.

RADIATION

Brachytherapy

Brachytherapy: Low or high dose rate.

Trial Locations (11)

Fundación IMOR, Barcelona

H. de la Santa Creu i Sant Pau, Barcelona

ICO Institut Català d'Oncologia-Hospitalet, L'Hospitalet de Llobregat

H. Ramón y Cajal, Madrid

H. Sanchinarro, Madrid

H. Carlos Haya, Málaga

Complejo Hospitalario de Navarra, Pamplona

Instituto Oncológico, San Sebastián

H. Universitario Marqués de Valdecilla, Santander

IVO Instituto Valenciano de Oncología, Valencia

H. Do Meixoeiro, Vigo